The year 2021 was the second year of the COVID-19 pandemic and the third year elexacaftor/tezacaftor/ivacaftor was available for people with CF.  The 2021 Registry data reflect a
combination of factors that impacted the lives of people with CF during the year. The favorable trends in lung function, pulmonary exacerbations, infection rates, and survival that were observed in 2020 data continued in 2021. These are strong indicators that broad uptake of elexacaftor/tezacaftor/ivacaftor is contributing to better health outcomes

Some highlights: 

Mean lung function is up 13% for 10 year olds, 24% for 18 year olds and 27% for 30 year olds.  

Predicted survial has increased by 20 years since the year 2000.  

Chronic pseudomonas infection has been reduced from 43% to 28%. 

Over half of CF adults now have a job.  

Pregancy rates have more than doubled.  

CF exacerbations have been cut in half.  

Lung transplants have been reduced by 2/3!

This news is all really amazing.

Ryan Thomas